VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ERIC 2022 | Identifying new CLL therapeutic targets by focusing on the evolution of cancer cells

Nicholas Chiorazzi, MD, Feinstein Institute for Medical Research, Manhasset, NY, discusses how further understanding the basic biologic parameters of cancer cells could help identify novel therapeutic agents for chronic lymphocytic leukemia (CLL). Prof. Chiorazzi describes how leukemic B cells’ interactive abilities with other cells change as they mature, thus devising therapies that can target both immature and mature cells could be a future approach in the quest for new CLL agents. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter